Adalimumab: Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira^® and Upadacitinib: Tablet 15 mg; Rinvoq^®

Page last updated: 17 March 2023

• Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 503KB)
• Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 134KB)